Loading clinical trials...

Impact of Neuropsychological Disorders in Multiple Sclerosis | Clinical Trials | Clareo Health

COMPLETEDNA

Impact of Neuropsychological Disorders in Multiple Sclerosis

Impact of Neuropsychological Disorders on Visual Exploration, Walking Initiation and Walking in Multiple Sclerosis

NCT04837365•Lille Catholic University

Summary

The study involves MS patients with and without neuropsychological disorders. The patient will benefit from: * A routine neuropsychological assessment, including a cognitive and emotional assessment * A clinical examination * A three-dimensional analysis of movement

Eligibility

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Understanding and able to speak French
•Carriers of MS with relapsing remitting form (RRMS-RR) with an EDSS \<4
•No significant motor, cerebellar or somesthesia disorders of the upper limbs or visual disturbances (side to a visual EDSS \<2)
•Absence of corticosteroid intake in the last four weeks
•Benefiting from health insurance coverage
•Not showing any flare-ups or worsening of the disease in the last 6 weeks
•No botulinum toxin injection for more than 4 months

Exclusion Criteria

•People with previous neurological pathologies, head trauma with loss of consciousness, psychiatric pathologies, serious general ailments, perceptual or dysarthric disorders preventing verbal communication or reading,
•Treatment with psychotropic drugs (except benzodiazepines and hypnotics).
•Refusal to participate after clear and fair information about the study.
•Adults under tutorship, curatorship or safeguard of justice
•With orthopedic treatment influencing walking
•Pregnant woman

Locations (3)

St Vincent hospital - neurological service

Lille, France

St Philibert hospital - Neurologial service

Lomme, France

St Philibert hospital - Physical Medicine and Rehabilitation

Lomme, France

Key Dates

Start Date

May 21, 2021

Primary Completion Date

November 7, 2025

Completion Date

December 7, 2025

Last Updated

March 11, 2026

Enrollment

ACTUAL participants

Conditions

Multiple Sclerosis

Interventions

Three dimensional gait analysis with eyetracking

OTHER

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504

Secondary Progressive Multiple Sclerosis (SPMS)

View study

RECRUITINGNA

Intermittent Hypoxia in Persons With Multiple Sclerosis

NCT06276634

Multiple SclerosisMultiple Sclerosis-Relapsing-Remitting+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 11, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Impact of Neuropsychological Disorders in Multiple Sclerosis

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Intermittent Hypoxia in Persons With Multiple Sclerosis

Factorial Optimization Trial to Test Cognitive Behavioral Therapy Components for Multiple Sclerosis Fatigue

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis

Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study